Further, plasma pTau-181, GFAP and NfL differentiate between AD, mild cognitive impairment, and control participants [7–9], and plasma pTau-181 and GFAP increase over time in preclinical AD [10]. This evidence concerns the gene NEFL and Alzheimer disease.